01—Abstract
Summary
Summary of the 8-K filed March 6, 2019. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on March 6, 2019, primarily to report its financial results for the fourth quarter and full year ended December 31, 2018, through a press release and a 2018 Shareholder Letter.
While the filing itself does not contain detailed financial figures, it directs investors to these supplementary documents for comprehensive information regarding the company's operational performance and financial condition during that period. Investors should review the furnished press release and shareholder letter for specific revenue, expense, and profitability data, as well as management's commentary on the company's progress and outlook. The filing also clarifies that the information provided in the press release and shareholder letter is furnished and not deemed "filed" under Section 18 of the Securities Exchange Act, meaning it's not subject to the same liability provisions.
This is standard practice for earnings releases and shareholder updates, but it's important for investors to note the distinction. The core value for investors lies within the content of the exhibits, which offer insights into Moderna's financial standing and strategic updates from late 2018.
02—Key points
Key Highlights
- Moderna filed an 8-K on March 6, 2019, to announce its Q4 and full-year 2018 financial results.
- The filing incorporates by reference a press release (Exhibit 99.1) detailing operational results and financial condition.
- A 2018 Shareholder Letter (Exhibit 99.2) is also furnished, providing additional context and management perspectives.
- Investors need to refer to the content of Exhibit 99.1 and Exhibit 99.2 for specific financial data and performance analysis.
- The information furnished is not considered 'filed' for purposes of Section 18 of the Exchange Act, a standard disclosure for such announcements.
- This 8-K serves as a notification and directs investors to the primary sources of financial and operational updates.
03—Questions
Frequently Asked Questions
Where can I find Moderna's Q4 and full-year 2018 financial results?
Moderna's Q4 and full-year 2018 financial results are detailed in the press release (Exhibit 99.1) and the 2018 Shareholder Letter (Exhibit 99.2) that are furnished with this 8-K filing dated March 6, 2019. You will need to access these exhibits for the specific financial figures and management commentary.
What is the significance of the information being 'furnished' rather than 'filed'?
When information is 'furnished' as part of an 8-K filing, it means the company is providing the information to the SEC and the public but it is not subject to the same liability provisions as 'filed' information, particularly under Section 18 of the Securities Exchange Act of 1934. This is a common practice for earnings releases and shareholder letters, but it's important for investors to understand this distinction in regulatory treatment.
Does this 8-K filing contain the actual financial numbers for Q4 2018?
No, the 8-K filing itself primarily serves as a notification that financial results have been released. The detailed financial numbers, including revenue, expenses, and net income/loss for the fourth quarter and full year 2018, are contained within the accompanying press release (Exhibit 99.1) and the 2018 Shareholder Letter (Exhibit 99.2).
What kind of insights can I expect from the Shareholder Letter mentioned in the filing?
The 2018 Shareholder Letter (Exhibit 99.2) typically provides management's perspective on the company's performance, strategic progress, key achievements during the year, and outlook for the future. It often includes qualitative commentary that complements the quantitative financial data found in the press release.
04—Continue